Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Chelsea Therapeutics International, Ltd. (CHTP)
|
Add to portfolio |
|
|
|
| Price: |
$4.72
| | Metrics |
| OS: |
78.9
|
M
| |
|
|
| Market cap: |
$373
|
M
| |
|
|
|
Net cash:
|
$37.1
|
M
| |
$0.47
|
per share
|
|
EV:
|
$335
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($13.3)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-13 | Dec-31-12 | Dec-31-11 | Dec-31-10 | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 24.0 | 27.1 | 12.3 | 6.9 |
| Revenue growth | | | | -100.0% | -11.5% | 119.8% | 79.7% | 24.5% |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 6.4 | 5.3 | 16.5 | 9.5 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 17.6 | 21.8 | -4.2 | -2.7 |
| Gross margin | | | | | 73.5% | 80.5% | -33.8% | -38.9% |
| Selling, general and administrative | | | | | | | | |
| Sales and marketing | 1.1 | 7.2 | 8.1 | 2.5 | 2.3 | 1.6 | 1.3 | 0.6 |
| Research and development | 10.4 | 16.7 | 37.3 | 30.9 | | | | |
| General and administrative | 5.0 | 5.7 | 5.3 | 4.2 | 4.1 | 3.7 | 2.9 | 2.0 |
| EBIT | -16.4 | -29.6 | -50.6 | -37.5 | -30.4 | -32.4 | -16.5 | -9.5 |
| EBIT margin | | | | | -126.5% | -119.5% | -133.8% | -138.9% |
| Pre-tax income | -16.4 | -31.7 | -50.5 | -37.3 | -25.8 | -35.1 | -15.1 | -8.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -16.4 | -31.7 | -50.5 | -37.3 | -25.8 | -35.1 | -15.1 | -8.7 |
| Net margin | | | | | -107.4% | -129.4% | -122.3% | -126.3% |
| |
| Diluted EPS | ($0.24) | ($0.47) | ($0.84) | ($0.91) | ($0.82) | ($1.17) | ($0.66) | ($0.46) |
| Shares outstanding (diluted) | 68.8 | 66.9 | 60.1 | 41.2 | 31.5 | 30.0 | 22.9 | 18.8 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|